The tumor types being investigated were head and neck squamous cell carcinoma (HNSCC, n=41), cervical cancer (n=37) and locally advanced/metastatic urothelial (mUC, n=23) tumors. “It comes at a time when there is a stark unmet need for the many HNSCC patients not responding to front-line therapy. The study is enrolling patients primarily with either HNSCC or cervical tumors. HNSCC KOL EventCorbus will host an in-person and virtual HNSCC KOL event during ESMO25 to review and discuss the data. The FDA has granted two Fast Track designations to CRB-701 in HNSCC and cervical cancer.